HPV16 detection after oropharyngeal cancer treatment may increase risk for recurrence
the ONA take:
Patients with oropharyngeal cancer who were found to have detectable traces of human papillomavirus type 16 (HPV16) in their saliva after cancer treatment are at a higher risk for disease recurrence, according to a new study published in JAMA Oncology.
For the study, researchers enrolled 124 patients who had been diagnosed with oropharyngeal cancer. Participants had their saliva collected at diagnosis, after treatment, and at nine, 12, 18, and 24 months after diagnosis.
Results showed that 7% of those who had HPV16 DNA in their saliva at the time of diagnosis were found to still have HPV16 DNA following treatment.
The findings may help clinicians determine which patients require further treatment to reduce the risk for developing disease recurrence.
"It should be reassuring that most people who have been treated for HPV-related oropharyngeal cancers are cured and there is no HPV16 DNA detected in their mouths, but among those that did recur, this was an important potential predictor," says Gypsyamber D'Souza, PhD, an associate professor in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health and a member of the Sidney Kimmel Comprehensive Cancer Center.
Patients with oropharyngeal cancer who were found to have detectable traces of human papillomavirus type 16 (HPV16) in their saliva.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|